Results 201 to 210 of about 167,917 (334)
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova +9 more
wiley +1 more source
Chemoattractant-induced activation of c-fos gene expression in human monocytes. [PDF]
Y S Ho, W M Lee, Ralph Snyderman
openalex +1 more source
Objectives To verify the pathogenesis of the OGFRL1 loss‐of‐function variant (c.30del, p. F10Ffs*110) identified in a CRMO patient and investigate the underlying mechanism. Methods Whole exome sequencing and Sanger sequencing were performed to identify and confirm the variant.
Wen Xiong +9 more
wiley +1 more source
Ebselen Suppresses Breast Cancer Tumorigenesis by Inhibiting YTHDF1-Mediated c-Fos Expression. [PDF]
Vasukutty A, Bhattarai PY, Choi HS.
europepmc +1 more source
Etude de la dégradation et de la sumoylation de la proto-oncoprotéine c-FOS
Guillaume Bossis
openalex +1 more source
Regulation of c-fos and c-jun expression in the rat supraoptic nucleus
David Carter, David Murphy
openalex +2 more sources
New opportunities for bioscaffold‐enabled spinal cord injury repair
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi +11 more
wiley +1 more source
Immediate-early genes Arc and c-Fos show divergent brain-wide expression following contextual fear conditioning. [PDF]
Bulthuis NE +3 more
europepmc +1 more source
同種異系膵島移植におけるc-Fos/Activator protein-1阻害による免疫抑制効果に関する研究 [論文内容及び審査の要旨]
雅 吉田
openalex +1 more source
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng +5 more
wiley +1 more source

